Effects of paclitaxel on the growth of normal, polyposis, and cancerous human colonic epithelial cells

Cancer

Volumn 85, Issue 7, 1999, Pages 1454-1464

  Sheppard, Brett C ^a   Rutten, Michael J ^a,c   Meichsner, Camie L ^a   Bacon, Kathy D ^a   Leonetti, Patrick O ^a   Land, John ^a   Crass, Richard C ^a   Trunkey, Donald D ^a   Deveney, Karen E ^a   Deveney, Clifford W ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Caco 2 cells; Colon; Colonic cultures; Growth; Human; LoVo cells; P glycoprotein; Paclitaxel; Polyposis; T 84 cells

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL MEMBRANE; COLON; COLON CANCER; COLON MUCOSA; COLON POLYPOSIS; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL;

EID: 0033121102     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19990401)85:7<1454::aid-cncr5>3.0.co;2-%23     Document Type: Article

References (53)

1. Ferry DR. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Ther 1998;36:29-40.
2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
3. Kingston DG, Hawkins DR, Ovington L. New taxanes from Taxus brevifolia. J Nat Prod 1982;45:466-70.
4. Fields KK, Elfenbein GJ, Perkins JB, Ballester OF, Goldstein SC, Heimenz JW, et al. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer. Semin Oncol 1998;25(2 Suppl 4):1-6.
5. Colevas AD. Future directions in the treatment of squamous cell carcinoma of the head and neck: the role of UFT. Oncology (Huntingt) 1997;11(9 Suppl 10):86-9.
6. Choy H, Akerley W, Devore R. Paclitaxel, carboplatin and radiation therapy for non-small-cell lung cancer. Oncology (Huntingt) 1998;12(1 Suppl 2):80-6.
7. Clemons M, Leahy M, Valle J, Jayson G, Ranson M, Howell A. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur J Cancer 1997;33:2183-93.
8. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982;94:688-96.
9. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5(Suppl 6):S3-6.
10. Reinecke P, Corvin J, Gabbert HE, Gerharz CD. Antiproliferative effects of paclitaxel (Taxol) on human renal clear cell carcinomas in vitro. Eur J Cancer 1997;33:1122-9.
11. Shepherd FA, Eisenhauer E. Ifosfamide and paclitaxel combinations for the treatment of advanced non-small cell lung cancer. Semin Oncol 1998;25(1 Suppl 2):2-7.
12. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 1998;12:305-34.
13. Gottesman MM, Pastan I, Ambudkar SV. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 1996;6:610-7.
14. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-8.
15. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
16. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
17. Barinaga M. Peptide-guided cancer drugs show promise in mice. Science 1998;279:323-4.
18. Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 1998;41:497-504.
19. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998;16: 1494-7.
20. Gadducci A, Brunetti I, Cosio S, Giannessi PG, Genazzani AR, Conte P. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer. Anticancer Res 1997;17: 4703-8.
21. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
22. Villa R, Gornati D, Zaffaroni N, Veneroni S, Bidoli P, Severini A. Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. Anticancer Res 1997;17:961-8.
23. el Khyari S, Bourgarel V, Barra Y, Braguer D, Briand C. Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4. Biochem Biophys Res Commun 1997;231:751-4.
24. Banerjee S, Fallis AG, Brown DL. Differential effects of taxol on two human cancer cell lines. Oncol Res 1997;9:237-48.
25. Deveney CW, Rand-Luby L, Rutten MJ, Luttropp CA, Fowler WM, Land J, et al. Establishment of human colonic epithelial cells in long-term culture. J Surg Res 1996;64:161-9.
26. Kramer RA. Multidrug resistance in cancer cells: biochemical mechanisms. Gastroenterology 1989;96:1214-5.
27. Giardiello FM, Petersen GM, Piantadosi S, Gruber SB, Traboulsi EI, Offerhaus GJ, et al. APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. Gut 1997;40:521-5.
28. Hoskins J, DeHerdt SV, Moore RE, Bumol TF. The development and characterization of Vinca alkaloid-resistant Caco-2 human colorectal cell lines expressing mdr-1. Int J Cancer 1993;53:680-8.
29. Beaumont PO, Moore MJ, Ahmad K, Payne MM, Lee C, Riddick DS. Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin. Cancer Res 1998;58:947-55.
30. Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, et al. Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem 1992;206:137-49.
31. Hunter J, Hirst BH, Simmons NL. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. Br J Cancer 1991;64:437-44.
32. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48:1926-9.
33. Georges E, Bradley G, Gariepy I, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:152-6.
34. Kellen JA, Wong AC, Mirakian A. Immunohistochemical determination of P-glycoprotein in a rat mammary tumour treated with tamoxifen. In Vivo 1992;6:541-4.
35. Molinari A, Calcabrini A, Meschini S, Stringaro A, Del Bufalo D, Cianfriglia M, et al. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int J Cancer 1998;75:885-93.
36. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997;77:284-9.
37. Kim H, Barroso M, Samanta R, Greenberger L, Sztul E. Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol 1997;273(2 Pt 1):C687-702.
38. Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97:1211-8.
39. Caruso ML, Valentini AM, Armentano R, Pirrelli M. P-170 glycoprotein expression in gastric and colorectal carcinomas and normal mucosa: an immunocytochemical study. In Vivo 1995;9:133-8.
40. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8.
41. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87.
42. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
43. Kramer R, Weber TK, Morse B, Arceci R, Staniunas R, Steele G Jr., et al. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 1993; 67:959-68.
44. Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimazu H, et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst 1990; 82:1679-83.
45. Fillpits M, Suchomel RW, Dekan G, Stiglbauer W, Haider K, Depisch D, et al. Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br J Cancer 1997;75:208-12.
46. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100:1282-93.
47. Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, et al. P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 1997;88:738-42.
48. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 1997;94:11037-42.
49. Zhan Z, Scala S, Monks A, Hose C, Bates S, Fojo T. Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemother Pharmacol 1997;40:245-50.
50. Rand-Luby LB, Rutten MJ, Luttropp CA, Gordon MD, Sheppard BC, Crass RA, et al. The establishment and characterization of a human familial adenomatous polyposis cell line [abstract]. J Natl Med Assoc 1995;87:459.
51. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 1977;58:209-14.
52. Murakami H, Masui H. Hormonal control of human colon carcinoma cell growth in serum-free medium. Proc Natl Acad Sci U S A 1980;77:3464-8.
53. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trujillo JM. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res 1976; 36(2 Pt 1):467-75.